Welcome to our dedicated page for Adagene SEC filings (Ticker: ADAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagene Inc.'s SEC filings document its foreign-private-issuer reporting for a clinical-stage biotechnology company developing antibody-based cancer immunotherapies. Form 6-K reports furnish clinical-data releases for muzastotug, regulatory updates for MSS colorectal cancer development, full-year financial results, business updates and notices of scientific presentations.
The filings also cover capital-structure and financing matters, including ADS offerings, underwriting agreements and the ADS-to-ordinary-share relationship. Other disclosures include licensing and collaboration agreements using SAFEbody technology, share-based compensation and equity accounts, governance updates, clinical development risks and exhibits furnished under Exchange Act reporting rules.